Ketamine and suicidal ideation in depression: Jumping the gun?

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Depression and suicide are closely linked, with an unclear neurobiological basis.
• Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is used in anesthesia but also has abuse potential.
• Subanesthetic ketamine infusions show rapid antidepressant effects and suppress suicidal ideation in depressed patients.

Purpose of the Study:

• To review clinical trials on ketamine's effects on suicidal ideation in depression.
• To explore the molecular mechanisms behind ketamine's antidepressant and psychotomimetic actions.
• To highlight ketamine's potential in managing suicidal ideation and averting self-harm.

Main Methods:

• Review of clinical trials investigating ketamine for depression and suicidal ideation.
• Analysis of preclinical and clinical data on ketamine's neurobiological effects.
• Examination of molecular mechanisms underlying ketamine's therapeutic and psychotomimetic actions.

Main Results:

• Ketamine demonstrates rapid-onset antidepressant effects and significant suppression of suicidal ideation.
• Subanesthetic ketamine's neuropsychiatric profile supports its use in managing acute suicidal crises.
• Molecular mechanisms involve NMDA receptor antagonism, influencing neurotransmitter systems.

Conclusions:

• Subanesthetic ketamine shows promise for managing suicidal ideation in depression, potentially preventing self-harm.
• Neuroimaging studies are crucial to elucidate brain region-specific and temporal effects of ketamine in suicidal patients.
• Ketamine may serve as a valuable tool in rodent models to investigate the neurobiology of suicidal behavior.